{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,5]],"date-time":"2025-10-05T00:29:32Z","timestamp":1759624172735,"version":"build-2065373602"},"reference-count":38,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ejog.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Obstetrics & Gynecology and Reproductive Biology"],"published-print":{"date-parts":[[2024,1]]},"DOI":"10.1016\/j.ejogrb.2023.11.021","type":"journal-article","created":{"date-parts":[[2023,11,17]],"date-time":"2023-11-17T23:56:19Z","timestamp":1700265379000},"page":"102-106","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Cytoreductive surgery and perioperative intraperitoneal chemotherapy in recurrent ovarian cancer: 18\u00a0years of experience"],"prefix":"10.1016","volume":"292","author":[{"given":"Anastasios","family":"Liberis","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dimitrios","family":"Kyziridis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Apostolos","family":"Kalakonas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antonios-Apostolos","family":"Tentes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejogrb.2023.11.021_b0005","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.bpobgyn.2016.10.009","article-title":"Surgery for recurrent ovarian cancer: options and limits","volume":"41","author":"Sehouli","year":"2017","journal-title":"Best Pract Res Clin Obstet Gynaecol"},{"key":"10.1016\/j.ejogrb.2023.11.021_b0010","first-page":"7","article-title":"Cancer statistics, 2019","volume":"69","author":"Siegel","year":"2019","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.ejogrb.2023.11.021_b0015","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1016\/j.ygyno.2016.04.537","article-title":"Surgical management of recurrent ovarian cancer","volume":"142","author":"Suh","year":"2016","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.ejogrb.2023.11.021_b0020","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2012\/358341","article-title":"Cytoreductive surgery combined with hyperthermic intraperitoneal intraoperative chemotherapy in the treatment of advanced epithelial ovarian cancer","author":"Tentes","year":"2012","journal-title":"J Oncol"},{"key":"10.1016\/j.ejogrb.2023.11.021_b0025","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.ijgo.2006.05.005","article-title":"Imiquimod treatment of vulvitis circumscripta plasmacellularis","volume":"95","author":"Frega","year":"2006","journal-title":"Int J Gynecol Obstet"},{"key":"10.1016\/j.ejogrb.2023.11.021_b0030","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1007\/s004230050246","article-title":"Management of peritoneal-surface malignancy: the surgeon\u2019s role","volume":"384","author":"Sugarbaker","year":"1999","journal-title":"Langenbeck\u2019s Arch Surg"},{"key":"10.1016\/j.ejogrb.2023.11.021_b0035","doi-asserted-by":"crossref","first-page":"1570","DOI":"10.1245\/s10434-014-4157-9","article-title":"Cytoreductive surgery and HIPEC in recurrent epithelial ovarian cancer: a prospective randomized phase III study","volume":"22","author":"Spiliotis","year":"2015","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.ejogrb.2023.11.021_b0040","doi-asserted-by":"crossref","first-page":"2594","DOI":"10.1200\/JCO.21.00605","article-title":"Secondary cytoreduction and carboplatin hyperthermic intraperitoneal chemotherapy for platinum-sensitive recurrent ovarian cancer: an MSK Team Ovary Phase II Study","volume":"39","author":"Zivanovic","year":"2021","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejogrb.2023.11.021_b0045","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1097\/IGC.0000000000000664","article-title":"Heated intraperitoneal chemotherapy (HIPEC) for patients with recurrent ovarian cancer: a systematic literature review","volume":"26","author":"Hotouras","year":"2016","journal-title":"Int J Gynecol Cancer"},{"key":"10.1016\/j.ejogrb.2023.11.021_b0050","doi-asserted-by":"crossref","first-page":"e59","DOI":"10.3802\/jgo.2019.30.e59","article-title":"Pharmacokinetics of cisplatin during open and minimally-invasive secondary cytoreductive surgery plus HIPEC in women with platinum-sensitive recurrent ovarian cancer: a prospective study","volume":"30","author":"Petrillo","year":"2019","journal-title":"J Gynecol Oncol"},{"key":"10.1016\/j.ejogrb.2023.11.021_b0055","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1186\/1472-6947-13-72","article-title":"Appraisal of the Karnofsky Performance Status and proposal of a simple algorithmic system for its evaluation","volume":"13","author":"P\u00e9us","year":"2013","journal-title":"BMC Med Inform Decis Mak"},{"key":"10.1016\/j.ejogrb.2023.11.021_b0060","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1053\/ejso.2001.1152","article-title":"Cytoreduction and intraperitoneal chemotherapy for the management of peritoneal carcinomatosis, sarcomatosis and mesothelioma","volume":"28","author":"Begossi","year":"2002","journal-title":"Eur J Surg Oncol"},{"key":"10.1016\/j.ejogrb.2023.11.021_b0065","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1053\/ejso.2002.1380","article-title":"Peritoneal cancer index: a prognostic indicator of survival in advanced ovarian cancer","volume":"29","author":"Tentes","year":"2003","journal-title":"Eur J Surg Oncol"},{"key":"10.1016\/j.ejogrb.2023.11.021_b0070","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1097\/00000658-199501000-00004","article-title":"Peritonectomy procedures","volume":"221","author":"Sugarbaker","year":"1995","journal-title":"Ann Surg"},{"key":"10.1016\/j.ejogrb.2023.11.021_b0075","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1177\/030089161009600306","article-title":"Cytoreductive surgery and perioperative intraperitoneal chemotherapy in recurrent ovarian cancer","volume":"96","author":"Tentes","year":"2010","journal-title":"Tumori"},{"key":"10.1016\/j.ejogrb.2023.11.021_b0080","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1111\/j.1048-891x.2004.14008.x","article-title":"Long-term results of cytoreductive surgery for advanced and recurrent epithelial ovarian cancers and papillary serous carcinoma of the peritoneum","volume":"14","author":"Look","year":"2004","journal-title":"Int J Gynecol Cancer"},{"key":"10.1016\/j.ejogrb.2023.11.021_b0085","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1245\/s10434-011-1873-2","article-title":"A risk model for secondary cytoreductive surgery in recurrent ovarian cancer: an evidence-based proposal for patient selection","volume":"19","author":"Tian","year":"2012","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.ejogrb.2023.11.021_b0090","doi-asserted-by":"crossref","first-page":"336","DOI":"10.3802\/jgo.2015.26.4.336","article-title":"Role of aggressive surgical cytoreduction in advanced ovarian cancer","volume":"26","author":"Chang","year":"2015","journal-title":"J Gynecol Oncol"},{"key":"10.1016\/j.ejogrb.2023.11.021_b0095","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1102\/1470-7330.2007.0030","article-title":"Cytoreductive surgery in ovarian cancer","volume":"7","author":"Pomel","year":"2007","journal-title":"Cancer Imag"},{"key":"10.1016\/j.ejogrb.2023.11.021_b0100","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1177\/1758834010361333","article-title":"Review: practical considerations in ovarian cancer chemotherapy","volume":"2","author":"Cristea","year":"2010","journal-title":"Ther Adv Med Oncol"},{"key":"10.1016\/j.ejogrb.2023.11.021_b0105","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1016\/j.semcancer.2021.08.011","article-title":"Chemotherapy resistance in epithelial ovarian cancer: mechanisms and emerging treatments","volume":"77","author":"Marchetti","year":"2021","journal-title":"Semin Cancer Biol"},{"key":"10.1016\/j.ejogrb.2023.11.021_b0110","doi-asserted-by":"crossref","first-page":"1659","DOI":"10.1200\/JCO.21.02085","article-title":"Secondary cytoreductive surgery in platinum-sensitive recurrent ovarian cancer: a meta-analysis","volume":"40","author":"Baek","year":"2022","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejogrb.2023.11.021_b0115","doi-asserted-by":"crossref","first-page":"3258","DOI":"10.1245\/s10434-020-09226-7","article-title":"The role of secondary cytoreductive surgery in recurrent ovarian cancer: a systematic review and meta-analysis","volume":"28","author":"Marchetti","year":"2021","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.ejogrb.2023.11.021_b0120","doi-asserted-by":"crossref","first-page":"2123","DOI":"10.1056\/NEJMoa2103294","article-title":"Randomized trial of cytoreductive surgery for relapsed ovarian cancer","volume":"385","author":"Harter","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejogrb.2023.11.021_b0125","first-page":"9","article-title":"The road to technical proficiency in cytoreductive surgery for peritoneal carcinomatosis: risk-adjusted cumulative summation analysis","author":"Santullo","year":"2022","journal-title":"Front Surg"},{"key":"10.1016\/j.ejogrb.2023.11.021_b0130","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1097\/DCR.0000000000001003","volume":"61","author":"Paul","year":"2018","journal-title":"Dis Colon Rectum"},{"key":"10.1016\/j.ejogrb.2023.11.021_b0135","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1245\/s10434-006-9169-7","article-title":"Prognostic indicators for patients undergoing cytoreductive surgery and perioperative intraperitoneal chemotherapy for diffuse malignant peritoneal mesothelioma","volume":"14","author":"Yan","year":"2006","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.ejogrb.2023.11.021_b0140","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1136\/ijgc-00009577-200603000-00005","article-title":"Long-term survival in advanced ovarian carcinoma following cytoreductive surgery with standard peritonectomy procedures","volume":"16","author":"Tentes","year":"2006","journal-title":"Int J Gynecol Cancer"},{"key":"10.1016\/j.ejogrb.2023.11.021_b0145","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1245\/s10434-019-07626-y","article-title":"Preoperative risk score for predicting incomplete cytoreduction: a 12-institution study from the US HIPEC Collaborative","volume":"27","author":"Zaidi","year":"2020","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.ejogrb.2023.11.021_b0150","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1007\/978-1-4613-1247-5_23","article-title":"Clinical research methodologies in diagnosis and staging of patients with peritoneal carcinomatosis","volume":"82","author":"Jacquet","year":"1996","journal-title":"Cancer Treat Res"},{"key":"10.1016\/j.ejogrb.2023.11.021_b0155","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1056\/NEJMoa1708618","article-title":"Hyperthermic intraperitoneal chemotherapy in ovarian cancer","volume":"378","author":"van Driel","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejogrb.2023.11.021_b0160","doi-asserted-by":"crossref","first-page":"2617","DOI":"10.1245\/s10434-021-11087-7","article-title":"Cytoreductive surgery with or without HIPEC after neoadjuvant chemotherapy in ovarian cancer: a phase 3 clinical trial","volume":"29","author":"Antonio","year":"2022","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.ejogrb.2023.11.021_b0165","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1136\/ijgc-2020-001231","article-title":"Primary cytoreductive surgery with or without hyperthermic intraperitoneal chemotherapy (HIPEC) for FIGO stage III epithelial ovarian cancer: OVHIPEC-2, a phase III randomized clinical trial","volume":"30","author":"Koole","year":"2020","journal-title":"Int J Gynecol Cancer"},{"key":"10.1016\/j.ejogrb.2023.11.021_b0170","unstructured":"Centre Oscar Lambret. Phase III randomized clinical trial evaluating hyperthermic intraperitoneal chemotherapy (HIPEC) in ovarian cancer considering two different settings: primary debulking surgery (PDS) and interval debulking surgery (IDS). 2019. Available at: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03842982 clinicaltrials.gov (last accessed 1 April 2021)."},{"key":"10.1016\/j.ejogrb.2023.11.021_b0175","unstructured":"Hospices Civils de Lyon. Assessment of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in first or secondary platinum-resistant recurrent ovarian epithelial cancer. 2019. Available at: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03220932 clinicaltrials.gov (last accessed 1 April 2021)."},{"key":"10.1016\/j.ejogrb.2023.11.021_b0180","doi-asserted-by":"crossref","first-page":"2813","DOI":"10.3390\/diagnostics13172813","article-title":"Integrating artificial intelligence tools in the clinical research setting: the ovarian cancer use case","volume":"13","author":"Escudero Sanchez","year":"2023","journal-title":"Diagnostics"},{"key":"10.1016\/j.ejogrb.2023.11.021_b0185","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1038\/s41698-023-00432-6","article-title":"Artificial intelligence in ovarian cancer histopathology: a systematic review","volume":"7","author":"Breen","year":"2023","journal-title":"NPJ Precis Oncol"},{"key":"10.1016\/j.ejogrb.2023.11.021_b0190","first-page":"173","article-title":"Applications of artificial intelligence (AI) in ovarian cancer, pancreatic cancer, and image biomarker discovery","volume":"33","author":"Mikdadi","year":"2022","journal-title":"CancerBiomark"}],"container-title":["European Journal of Obstetrics & Gynecology and Reproductive Biology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0301211523008278?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0301211523008278?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,4]],"date-time":"2025-10-04T06:02:58Z","timestamp":1759557778000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0301211523008278"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1]]},"references-count":38,"alternative-id":["S0301211523008278"],"URL":"https:\/\/doi.org\/10.1016\/j.ejogrb.2023.11.021","relation":{},"ISSN":["0301-2115"],"issn-type":[{"type":"print","value":"0301-2115"}],"subject":[],"published":{"date-parts":[[2024,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cytoreductive surgery and perioperative intraperitoneal chemotherapy in recurrent ovarian cancer: 18\u00a0years of experience","name":"articletitle","label":"Article Title"},{"value":"European Journal of Obstetrics & Gynecology and Reproductive Biology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejogrb.2023.11.021","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}